PL EN


Preferences help
enabled [disable] Abstract
Number of results
2006 | 53 | 2 | 361-369
Article title

Expression of soluble recombinant TGF-β type II receptor fused with the Fc portion of human IgG1 (sTβRII-Fc) in NS0 cells

Content
Title variants
Languages of publication
EN
Abstracts
EN
We have constructed and expressed recombinant chimeric soluble TGF-β type II receptor fused with the Fc portion of human IgG1 (sTβRII-Fc) in NS0 mouse myeloma cells and isolated cell lines constitutively secreting very high levels of biologically active protein. The GS-NS0 expression system takes advantage of the strong human cytomegalovirus immediate early promoter expression vector and glutamine synthetase as a selectable marker. The recombinant chimeric receptor could be produced in high amounts and efficiently purified by one step chromatography on a protein A column. Biochemical studies revealed that recombinant sTβRII-Fc binds native TGF-β1 and TGF-β3 isoforms and neutralizes their activity in vitro.
Publisher

Year
Volume
53
Issue
2
Pages
361-369
Physical description
Dates
published
2006
received
2006-01-10
revised
2006-03-23
accepted
2006-05-10
(unknown)
2006-05-30
Contributors
  • Department of Cancer Diagnostics and Immunology, GreatPoland Cancer Center, Poznań, Poland
  • Department of Cancer Immunology, Chair of Medical Biotechnology, Poznań University of Medical Sciences, Poznań, Poland
  • Department of Cancer Diagnostics and Immunology, GreatPoland Cancer Center, Poznań, Poland
  • Department of Cancer Diagnostics and Immunology, GreatPoland Cancer Center, Poznań, Poland
References
  • Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT (1992) High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (NY) 10: 169-175.
  • Bibila TA, Robinson DK (1995) In pursuit of the optimal fed-batch process for monoclonal antibody production. Biotechnol Prog 11: 1-13.
  • Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Eng J Med 342: 1350-1358.
  • Border WA, Noble NA (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286-1292.
  • Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, Olson BA, Weinstock J, Laping NJ (2002) Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5). J Med Chem 45: 999-1001.
  • Chen S, Iglesias-de la Cruz MC, Jim B, Hong SW, Isono M, Ziyadeh FN (2003) Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice. Biochem Biophys Res Commun 300: 16-22.
  • Clouthier DE, Comerford SA, Hammer RE (1997) Hepatic fibrosis, glomerulosclerosis, and lipodystrophy-like PEPCK-TGF-beta-1 transgenic mice. J Clin Invest 100: 2697-2713.
  • de Visser KE, Kast WM (1999) Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 13: 1188-1199.
  • Dempsey J, Ruddock S, Osborne M, Ridley A, Sturt S, Field R (2003) Improved fermentation processes for NS0 cell lines expressing human antibodies and glutamine synthetase. Biotechnol Prog 19: 175-178.
  • Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129.
  • Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE (1996) Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 93: 2909-2914.
  • Flanders KC, Burmester JK (2003) Medical applications of transforming growth factor-beta. Clin Med Res 1: 13-20.
  • Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7: 1118-1122.
  • Han G, Lu S-L, Li AG, He W, Corless CL, Kulesz-Martin M, Wang X-J (2005) Distinct mechanisms of TGF-beta-1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest 115: 1714-1723.
  • Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A (2001) Transforming growth factor-β2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 170: 647-651.
  • Huang JS, Wang YH, Ling TY, Chuang SS, Johnson FE, Huang SS (2002) Synthetic TGF-beta antagonist accelerates wound healing and reduces scarring. FASEB J 16: 1269-1270.
  • Kaminski N, Allard JD, Pittet JF, Zuo F, Griffiths MJ, Morris D, Huang X, Sheppard D, Heller RA (2000) Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci 97: 1778-1783.
  • Kolb M, Margetts PJ, Galt T, Sime PJ, Xing Z, Schmidt M, Gauldie J (2001) Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med 163: 770-777.
  • Kosuga K, Tamai H, Ueda K, Hsu YS, Ono S, Tanaka S, Doi T, Myou-U W, Motohara S, Uehata H (1997) Effectiveness of tranilast on restenosis after directional coronary atherectomy. Am Heart J 134: 712-718.
  • Kowalczyk DW, Wlazlo AP, Giles-Davis W, Ertl HC (2000) Staining of antigen activated lymphocytes (SAAL): a highly specific method for flow cytometric quantitation of tumor-specific CD8(+) T cells. J Immunol Methods 241: 131-139.
  • Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S (1993) Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90: 770-774.
  • Kulkarni AB, Ward JM, Yaswen L, Mackall CL, Bauer SR, Huh CG, Gress RE, Karlsson S (1995) Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am J Pathol 146: 264-275.
  • Li AG, Wang D, Feng X-H, Wang X-J (2004) Latent TGF-beta-1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J 23: 1770-1781.
  • Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF (1992) Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell 68: 775-785.
  • Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS (2005) Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 23: 5950-5959.
  • Maggard M, Meng L, Ke B, Allen R, Devgan L, Imagawa DK (2001) Antisense TGF-β2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model. Ann Surg Oncol 8: 32-37.
  • Massague J (1990) The transforming growth factor-beta family. Annu Rev Cell Biol 6: 597-641.
  • Massague J (1992) Receptors for the TGF-beta family. Cell 69: 1067-1070.
  • Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169-178.
  • Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D (1999) The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319-328.
  • Nash PT, Florin TH (2005) Tumour necrosis factor inhibitors. Med J Aust 183: 205-208.
  • Reeves WB, Andreoli TE (2000) Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci 97: 7667-7669.
  • Ruegemer JJ, Ho SN, Augustine JA, Schlager JW, Bell MP, McKean DJ, Abraham RT (1990) Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression. J Immunol 144: 1767-1776.
  • Sakamoto T, Ueno H, Sonoda K, Hisatomi T, Shimizu K, Ohashi H, Inomata H (2000) Blockade of TGF-β by in vivo gene transfer of a soluble TGF-β type II receptor in the muscle inhibits corneal opacification, edema and angiogenesis. Gene Ther 7: 1915-1924.
  • Shah M, Revis D, Herrick S, Baillie R, Thorgeirson S, Ferguson M, Roberts A (1999) Role of elevated plasma transforming growth factor-beta1 levels in wound healing. Am J Pathol 154: 1115-1124.
  • Sharma K, Jin Y, Guo J, Ziyadeh FN (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530.
  • Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
  • Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D (1992) Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693-699.
  • Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807-821.
  • Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J (2003) Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100: 8430-8435.
  • Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 352: 351-361.
  • Wojtowicz-Praga S (2003) Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 21: 21-32.
  • Ziyadeh FN, Hoffman BB, Han DC, Iglesias-de la Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv53p361kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.